21st.BIO A/S - CVR: 41554908

2023, DKK

13.05.2024

Bruttoresultat

-9.826'

Primær drift

-48.068'

Årets resultat

-42.260'

Aktiver

419''

Kortfristede aktiver

154''

Egenkapital

295''

Afkastningsgrad

-11 %

Soliditetsgrad

70 %

Likviditetsgrad

+500%

Resultat

13.05.2024

Årsrapport	2023 13.05.2024	2022 23.05.2023	2020 27.05.2022
Nettoomsætning
Bruttoresultat	-9.825.858	-21.930.501	-19.455.071
Resultat af primær drift	-48.067.919	-55.446.884	-22.263.534
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0
Finansielle indtægter	7.643.229	304.185	85.558
Finansieringsomkostninger	0	0	0
Andre finansielle omkostninger	-3.224.651	-817.651	-80.835
Resultat før skat	-48.467.831	-54.208.668	0
Resultat	-42.260.118	-36.612.241	-21.795.858
Forslag til udbytte	0	0	0

Aktiver

13.05.2024

Årsrapport	2023 13.05.2024	2022 23.05.2023	2020 27.05.2022
Kortfristede varebeholdninger	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	70.771.987	25.792.104	7.613.040
Likvider	82.873.903	49.286.568	24.302.544
Kortfristede aktiver	153.645.890	75.078.672	31.915.584
Immaterielle aktiver og goodwill	243.740.179	245.453.520	0
Finansielle anlægsaktiver	1.421.455	3.432.577	521.711
Materielle aktiver	20.392.911	5.423.207	1.527.019
Langfristede aktiver	265.554.545	254.309.304	2.048.730
Aktiver	419.200.435	329.387.976	33.964.314

Aktiver

13.05.2024

Passiver

13.05.2024

Årsrapport	2023 13.05.2024	2022 23.05.2023	2020 27.05.2022
Forslag til udbytte	0	0	0
Egenkapital	294.808.764	262.615.831	23.854.142
Hensatte forpligtelser	55.514.216	54.185.278	0
Langfristet gæld til banker	0	0	0
Anden langfristet gæld		0	0
Leverandører af varer og tjenesteydelser	14.705.821	11.777.539	9.054.049
Kortfristede forpligtelser	22.341.162	12.586.867	10.110.172
Gældsforpligtelser	0	12.586.867	10.110.172
Forpligtelser	0	12.586.867	10.110.172
Passiver	419.200.435	329.387.976	33.964.314

Passiver

13.05.2024

Nøgletal

13.05.2024

Årsrapport	2023 13.05.2024	2022 23.05.2023	2020 27.05.2022
Afkastningsgrad	-11,5 %	-16,8 %	-65,5 %
Dækningsgrad	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.
Egenkapitals-forretning	-14,3 %	-13,9 %	-91,4 %
Payout-ratio	Na.	Na.	Na.
Gældsdæknings-nøgletal	Na.	Na.	Na.
Soliditestgrad	70,3 %	79,7 %	70,2 %
Likviditetsgrad	687,7 %	596,5 %	315,7 %

Resultat

13.05.2024

Gæld

13.05.2024

Årsrapport

13.05.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 13.05.2024)

Information om virksomhedens regnskabsklasse:This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises with addition of a few provisions for reporting class C. The accounting policies applied to these consolidated financial statements and parent financial statements are consistent with those applied last year.

Oplysning om pantsætninger og sikkerhedsstillelser:12 Assets charged and collateralMortgage debt is secured by way of mortgage on assets and collateral amounting to DKK 45,000,000.

Beretning

13.05.2024

Dato for ledelsens godkendelse af årsrapporten:2024-05-08

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Board of Directors and the Executive Board have today considered and approved the annual report of 21st. BIO A/S for the financial year 01. 01. 2023 - 31. 12. 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Primary activities21st. BIO is a bio-industrial scale-up company founded on a mission to support biotech companies across the globe to upscale their molecule innovations to large-scale production. This allows our customers to compete effectively and meet market demands for biobased solutions with new functionality, in turn allowing us to jointly advance the green transition together. The focus areas of 21st. BIO include proteins and peptides that can be utilized for the food, materials, and agricultural industries. 21st. BIO builds on select industrially proven technologies from Novonesis (former Novozymes A/S), which we use to develop our customers’ expression platform and processes for large-scale production of their molecule innovation. This is done by testing the target molecule in our various expression platforms within fungi, yeast or bacteria. With the right expression platform identified, our expert science team draws on a comprehensive strain bank and selects and optimizes the best-performing strains and develops a downstream process for it. This leads to an optimized production platform that enables customers to produce their product at commercially attractive costs and quantities, in turn leading to an increase in the likelihood of a successful launch and a decrease in time to market.